Abdominal Radiology

, Volume 44, Issue 1, pp 85–94 | Cite as

Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings

  • Matthieu BayleEmail author
  • Isabelle Clerc-Urmès
  • Ahmet Ayav
  • Jean-Pierre Bronowicki
  • Isabelle Petit
  • Xavier Orry
  • Valérie Laurent



The aim of this study was to assess hepatocellular carcinoma (HCC) response with CT perfusion parameters before and after two transarterial chemo embolization (TACE) courses compared with MRI, and to search for predictive factors of response.


37 lesions (19 patients) were included between October 2015 and September 2017, based on the Barcelona Clinic Liver Cancer guidelines. CT perfusion with 160-mm coverage and MRI were performed before and after the first TACE course, and after the second TACE course. Quantitative perfusion parameters were compared to the response assessed with MRI using mRECIST criteria, defining response groups: complete response (CR), partial response (PR), no response (NR), response (including CR and PR), no complete response (NCR, including PR and NR).


Pre-TACE blood flow (BF) and hepatic arterial blood flow (HABF) were significantly higher in lesions with post-TACE 1 CR than in those with NCR (BF: 118.8 vs. 76.3 mL/100 g/min, p = 0.0231; HABF: 76 vs. 44.2 mL/100 g/min, p = 0.0112). Pre-TACE time to peak (TTP) and mean transit time (MTT) were significantly lower in lesions with post-TACE 2 response than in those with NR (TTP: 31.5 vs. 46.1 s, p = 0.0313; MTT: 15.8 vs. 22.8 s, p = 0.0204). Post-TACE 1 and post-TACE 2 perfusion parameters did not exhibit any statistically significant differences relative to MRI response.


Our study did not find, after a first TACE course, perfusion parameters associated with a response to a second TACE course. However, baseline perfusion parameters analysis could lead to better therapeutic management of HCC by targeting lesions likely to respond well to TACE courses.


Hepatocellular carcinoma Transarterial chemoembolization Perfusion imaging Computed tomography Magnetic resonance imaging 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. For this type of study formal consent is not required.

Supplementary material

261_2018_1714_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 20 kb)


  1. 1.
    El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142(1264–1273):e1. Google Scholar
  2. 2.
    Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022. Google Scholar
  3. 3.
    Heimbach JK, Kulik LM, Finn RS, et al. (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380. Google Scholar
  4. 4.
    European Association For The Study of The Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943. Google Scholar
  5. 5.
    Yaghmai V, Besa C, Kim E, et al. (2013) Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. AJR Am J Roentgenol 201:80–96. Google Scholar
  6. 6.
    Ippolito D, Capraro C, Casiraghi A, Cestari C, Sironi S (2012) Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging. Eur Radiol 22:803–811. Google Scholar
  7. 7.
    García-Figueiras R, Goh VJ, Padhani AR, et al. (2013) CT perfusion in oncologic imaging: a useful tool? AJR Am J Roentgenol 200:8–19. Google Scholar
  8. 8.
    Kim SH, Kamaya A, Willmann JK (2014) CT perfusion of the liver: principles and applications in oncology. Radiology 272:322–344. Google Scholar
  9. 9.
    Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV (2012) Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 47:11–17. Google Scholar
  10. 10.
    Kaufmann S, Thaiss WM, Schulze M, et al. (2017) Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up. Acta Radiol . Google Scholar
  11. 11.
    Ippolito D, Bonaffini P-A, Ratti L, et al. (2010) Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor. World J. Gastroenterol 16:5993–6000Google Scholar
  12. 12.
    Lladó L, Virgili J, Figueras J, et al. (2000) A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 88:50–57Google Scholar
  13. 13.
    Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442. Google Scholar
  14. 14.
    Marelli L, Stigliano R, Triantos C, et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25. Google Scholar
  15. 15.
    Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K (1991) Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 68:2150–2154Google Scholar
  16. 16.
    Ippolito D, Sironi S, Pozzi M, et al. (2008) Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization. Acad Radiol 15:919–927. Google Scholar
  17. 17.
    Yang HF, Du Y, Ni JX, et al. (2010) Perfusion computed tomography evaluation of angiogenesis in liver cancer. Eur Radiol 20:1424–1430. Google Scholar
  18. 18.
    Yang L, Zhang X, Tan B, et al. (2012) Computed tomographic perfusion imaging for the therapeutic response of chemoembolization for hepatocellular carcinoma. J Comput Assist Tomogr 36:226–230. Google Scholar
  19. 19.
    Marquez HP, Karalli A, Haubenreisser H, et al. (2017) Computed tomography perfusion imaging for monitoring transarterial chemoembolization of hepatocellular carcinoma. Eur J Radiol 91:160–167. Google Scholar
  20. 20.
    Ippolito D, Fior D, Bonaffini PA, et al. (2014) Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol 83:1665–1671. Google Scholar
  21. 21.
    Ippolito D, Fior D, Franzesi CT, et al. (2014) Tumour-related neoangiogenesis: functional dynamic perfusion computed tomography for diagnosis and treatment efficacy assessment in hepatocellular carcinoma. Dig Liver Dis 46:916–922. Google Scholar
  22. 22.
    Du F, Jiang R, Gu M, He C, Guan J (2015) The clinical application of 320-detector row CT in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma. Radiol Med 120:690–694. Google Scholar
  23. 23.
    Kloeckner R, Otto G, Biesterfeld S, et al. (2010) MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:532–540. Google Scholar
  24. 24.
    Kaufmann S, Horger T, Oelker A, et al. (2015) Volume perfusion computed tomography (VPCT)-based evaluation of response to TACE using two different sized drug eluting beads in patients with nonresectable hepatocellular carcinoma: impact on tumor and liver parenchymal vascularisation. Eur J Radiol 84:2548–2554. Google Scholar
  25. 25.
    Tamandl D, Waneck F, Sieghart W, et al. (2017) Early response evaluation using CT-perfusion 1 day after transarterial chemoembolization for HCC predicts treatment response and long-term disease control. Eur J Radiol 90:73–80. Google Scholar
  26. 26.
    Wimmer T, Steiner J, Talakic E, et al. (2017) Computed tomography perfusion following transarterial chemoembolization of hepatocellular carcinoma: a feasibility study in the early period. J Comput Assist Tomogr 41:708–712. Google Scholar
  27. 27.
    Syha R, Grözinger G, Grosse U, et al. (2016) Parenchymal blood volume assessed by C-arm-based computed tomography in immediate posttreatment evaluation of drug-eluting bead transarterial chemoembolization in hepatocellular carcinoma. Invest Radiol 51:121–126. Google Scholar
  28. 28.
    Rathmann N, Kara K, Budjan J, et al. (2017) Parenchymal liver blood volume and dynamic volume perfusion CT measurements of hepatocellular carcinoma in patients undergoing transarterial chemoembolization. Anticancer Res 37:5681–5685. Google Scholar
  29. 29.
    Yang L, Zhang XM, Zhou XP, et al. (2010) Correlation between tumor perfusion and lipiodol deposition in hepatocellular carcinoma after transarterial chemoembolization. J Vasc Interv Radiol 21:1841–1846. Google Scholar
  30. 30.
    Su T-H, He W, Jin L, Chen G, Xiao G-W (2017) Early response of hepatocellular carcinoma to chemoembolization: volume computed tomography liver perfusion imaging as a short-term response predictor. J Comput Assist Tomogr 41:315–320. Google Scholar
  31. 31.
    Bai R-J, Li J-P, Ren S-H, et al. (2014) A correlation of computed tomography perfusion and histopathology in tumor edges of hepatocellular carcinoma. HBPD INT 13:612–617Google Scholar
  32. 32.
    Sahani DV, Holalkere N-S, Mueller PR, Zhu AX (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue–initial experience. Radiology 243:736–743. Google Scholar
  33. 33.
    Martins-Filho SN, Paiva C, Azevedo RS, Alves VAF (2017) Histological grading of hepatocellular carcinoma-a systematic review of literature. Front Med (Lausanne) 4:193. Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of RadiologyCHRU Nancy, Brabois Adults HospitalVandoeuvre-lès-NancyFrance
  2. 2.Biostatistics Unit (PARC)CHRU NancyVandoeuvre-lès-NancyFrance
  3. 3.Department of HBP SurgeryCHRU Nancy, Brabois Adults HospitalVandoeuvre-lès-NancyFrance
  4. 4.Université de Lorraine, Faculté de MédecineVandoeuvre-lès-NancyFrance
  5. 5.Department of Hepato-gastroenterologyCHRU Nancy, Brabois Adults HospitalVandoeuvre-lès-NancyFrance
  6. 6.INSERM, U954Vandoeuvre-lès-NancyFrance
  7. 7.INSERM, U947, IADIVandoeuvre-lès-NancyFrance

Personalised recommendations